s it pursues Mylan Pharmaceuticals for $100 million in taxes, the Internal Revenue Service is accusing the drug maker of bad faith in complying with ongoing requests to cough up documents needed for a looming trial.

In court documents filed last month, the IRS alleges that Mylan has “repeated false assurances and [offered] incomplete responses” to its efforts to obtain materials over the past two years. And the failure to produce the documents is “inexcusable,” the IRS wrote in a motion asking the US Tax Court to force the company to turn over emails, correspondence, and other paperwork (see here, here and here).

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.